Eris Lifesciences Limited has successfully completed its acquisition of the probiotics business from Velbiom Probiotics Private Limited, the pharmaceutical company announced to stock exchanges on March 31, 2026. The transaction closure follows the company's earlier intimation to exchanges dated March 20, 2026.

Transaction Completion Details

The acquisition has been completed to the extent and in the manner outlined in the company's original March 20, 2026 communication to the exchanges. The regulatory filing confirms that all necessary procedures for the transaction closure have been fulfilled.

Regulatory Compliance

The update was filed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. Company Secretary & Compliance Officer Milind Talegaonkar (Membership No: A26493) digitally signed the filing on March 31, 2026.

Exchange Communication

Eris Lifesciences communicated the transaction completion to both major Indian stock exchanges:

• BSE Limited (Security Code: 540596)
• National Stock Exchange of India Limited (Symbol: ERIS)

The company emphasized that this information is provided for the exchanges' information and record purposes, ensuring transparency with stakeholders regarding the completed acquisition.

Eris Lifesciences Limited has announced the execution of a corporate guarantee worth INR 75 crores for its wholly owned subsidiary, Eris Bionxt Private Limited (EBPL). The guarantee secures a term loan sanctioned by HDFC Bank, with proceeds earmarked for repaying EBPL's existing loan liabilities.

Corporate Guarantee Details

The company disclosed the guarantee execution under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal communication was made to both BSE Limited and National Stock Exchange of India Limited on March 27, 2026.

Transaction Structure and Impact

The corporate guarantee arrangement involves no interest from promoters, promoter groups, or group companies in the transaction. EBPL, being a wholly owned subsidiary, has its financials consolidated with Eris Lifesciences' accounts.

Key Transaction Features:

• Relationship: EBPL is a wholly owned subsidiary of Eris Lifesciences
• Promoter Interest: No promoter or group company involvement
• Financial Treatment: Guarantee appears as contingent liability in standalone financials
• Loan Purpose: Repayment of existing loan liabilities by EBPL

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 requirements and SEBI Master circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Company Secretary and Compliance Officer Milind Talegaonkar signed the regulatory filing, ensuring proper documentation and transparency.

The guarantee details have been uploaded to the company's website as part of standard disclosure practices. This corporate guarantee represents a strategic financial support mechanism for the subsidiary's debt restructuring activities while maintaining consolidated financial reporting standards.